Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 9/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6283621 | 1.00 | KMT2A (0.38) | KMT2ATDP1KDM4ECCR5MEN1 | |
| SCHEMBL6280897 | 0.87 | KMT2A (0.45) | KMT2ATDP1KDM4EMEN1HTT | |
| SCHEMBL6280894 | 0.87 | KMT2A (0.45) | KMT2ATDP1KDM4EMEN1HTT | |
| SCHEMBL6282361 | 0.84 | ALDH1A1 (0.35) | KMT2ATDP1KDM4ECCR5ALDH1A1 | |
| SCHEMBL6282363 | 0.84 | ALDH1A1 (0.35) | KMT2ATDP1KDM4ECCR5ALDH1A1 | |
| SCHEMBL6280081 | 0.74 | CYP3A4 (0.47) | KMT2AMEN1HTTNPC1ALDH1A1 | |
| SCHEMBL6280085 | 0.74 | CYP3A4 (0.47) | KMT2AMEN1HTTNPC1ALDH1A1 | |
| SCHEMBL21575681 | 0.73 | OPRK1 (0.57) | KMT2AALDH1A1CYP2D6OPRK1 | |
| SCHEMBL16586048 | 0.71 | KDM4E (0.47) | KMT2ATDP1KDM4EMEN1NPSR1 | |
| SCHEMBL18171429 | 0.68 | OPRK1 (0.47) | CYP2D6OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852713-B2 | Lactam derivatives and methods of their use | ADOLOR CORPORATION (US) | 2005-02-08 | — | — | US | disclosed |
| WO-2004093796-A2 | LACTAM DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040209857-A1 | Lactam derivatives and methods of their use | ADOLOR CORPORATION | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209857-A1 | Lactam derivatives and methods of their use | MRPL21, SI, PEPD | KMT2A 4525/4885TDP1 2801/4885KDM4E 4146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.